LENZ Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Securities Trading Plans of Directors and Executive Officers
On August 11, 2025, Evert Schimmelpennink, Chief Executive Officer of the Company, entered into a 10b5-1 trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. This 10b5-1 trading plan provides for the sale of 225,000 shares of the Company’s common stock related to the exercise of option awards granted to Mr. Schimmelpennink. This 10b5-1 trading plan will become effective on January 19, 2026 and will terminate on June 30, 2026, subject to earlier termination as provided in the plan.
On August 12, 2025, Shawn Olsson, Chief Commercial Officer of the Company, entered into a 10b5-1 trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. This 10b5-1 trading plan provides for the sale of 66,891 shares of the Company’s common stock related to the exercise of option awards granted to Mr. Olsson. This 10b5-1 trading plan will become effective on November 17, 2025 and will terminate on October 19, 2026, subject to earlier termination as provided in the plan.
During our last fiscal quarter, none of our other directors or officers, as defined in Rule 16a-1(f), adopted and/orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.